HIV heart risk targeted: new drug shows promise in artery health
NCT ID NCT03207945
First seen Jan 05, 2026 · Last updated May 20, 2026 · Updated 25 times
Summary
This study tested a drug called alirocumab in 118 people with HIV who were at risk for heart disease. The drug aims to lower cholesterol and reduce inflammation in the arteries, which can lead to heart attacks. Participants received either the drug or a placebo for about a year, and researchers used special scans to check artery health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
San Francisco General Hospital
San Francisco, California, 94110, United States
Conditions
Explore the condition pages connected to this study.